You can find original article here WealthManagement. Subscribe to our free daily WealthManagement newsletters. (Bloomberg) -- JPMorgan Chase & Co.’s asset management arm is pitching private markets as essential ballast to investor portfolios amid stretched stock valuations and unreliable bond hedges. With stock gains increasingly driven by a handful of large caps and bonds potentially offering less protection in downturns, the traditional 60/40 portfolio mix needs reinforcement, the $4 trillion asset man ...

CONCLUDED Stock Market News From Nov. 20, 2025: Nasdaq Sinks 2.2% as Nvidia Bump Evaporates Last Updated: 3 hours ago Nasdaq Falls 2.2%, Gives Up Early 2.6% Gain, as Nvidia Rally Fizzles By Connor Smith An early stock market rally fueled by Nvidia's earnings turned out to be a mirage on Thursday. The Nasdaq Composite sank 2.2%. The S&P 500 fell 1.6%. The Dow Jones Industrial Average dropped 386 points, or 0.8%. At one point, the Nasdaq was up 2.6%, while the S&P was up 1.9% and the Dow was up 1.6%; all thre ...

Key Points Bitcoin drawdowns are too sudden and extreme for retirees. Gold tends to do well during bad times. Retirees could make Bitcoin a relatively small, five-to-ten-year bet. These 10 stocks could mint the next wave of millionaires › Bitcoin (CRYPTO: BTC) is building a reputation as the digital equivalent of gold. U.S. Treasury Secretary Scott Bessent has said, "Gold is a store of value, Bitcoin is becoming a store of value." Like gold, Bitcoin is considered an excellent long-term store of va ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 20, 2025 /PRNewswire/ -- S&P Global (NYSE: SPGI)Â today announced the launch of WSO Compliance Insights, a comprehensive compliance management solution designed to enhance credit risk management for private credit and CLO managers. This application, available through S&P Global Market Intelligence, utilizes real-time data streaming, enabling users to streamline compliance processes, eliminate end- of-day batch processing and improve decision-making capab ...

The market on close. Taking another look at Nvidia. The stock has dropped significantly from its pre-market highs of $198.[music] The company did post another beat and raise on its earnings report. CEO Jensen Wong dismissing talk of an AI bubble on the call, saying, quote, "From our vantage point, we see something very [music] different." Now, what we have seen today is very different trading action in Nvidia. It's been all over the place.So, that means it's time for Options Corner. We'll take a closer look ...

Corporate Profile Stepan Company is a major manufacturer of specialty and intermediate chemicals used in a broad range of industries. Stepan is a leading merchant producer of surfactants, which are the key ingredients in consumer and industrial cleaning and disinfection compounds and in agricultural and oilfield solutions. The Company is also a leading supplier of polyurethane polyols used in the expanding thermal insulation market, and CASE (Coatings, Adhesives, Sealants, and Elastomers) industries. Headqu ...

Accessibility StatementSkip Navigation Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference: Piper Sandler 37th... RICHMOND, Va., Nov. 20, 2025 /PRNewswire/ --Â Indivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding obligation of $295 million associated with the matter. With the DOJ's receipt of the payment, the resolution agreement with t ...

Core Insights - Olema Pharmaceuticals, Inc. has successfully closed an underwritten public offering of 11,500,000 shares of common stock at a price of $19.00 per share, generating gross proceeds of approximately $218.5 million before expenses [1]. Company Overview - Olema Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer and other endocrine-driven cancers. The company is advancing a pipeline that includes its lead product candidate, palazestrant (OP-1250), which is currently in two Phase 3 clinical trials, and OP-3136, a KAT6 inhibitor in Phase 1 clinical study [5].

-- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation has achieved stable disease and remains on trial for more than 6 months -- -- Initial Disease Control Rate in efficacy evaluable patients of 71.4% with BRAF-mutated tumors: 5 of 7 patients achieved stable disease -- -- Favorable Safety Profile: PAS-0 ...

Accessibility StatementSkip Navigation IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- American Healthcare REIT, Inc. (NYSE: AHR; the "Company") announced today that it has commenced an underwritten public offering of 8,100,000Â shares of its common stock on a forward basis in connection with the forward sale agreement described below. RBC Capital Markets is acting as the underwriter for the offering. In connection with the offering, the Company expects to enter into a forward sale agreement with RBC Capital ...